Collegium Pharmaceutical Inc (COLL)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 69,190 | 88,594 | 99,893 | 93,294 | 48,155 | 9,016 | -11,161 | -29,359 | -25,002 | -42,837 | -35,248 | 42,786 | 71,517 | 103,509 | 106,749 | 41,964 | 26,752 | 17,593 | 198 | -12,572 |
| Total stockholders’ equity | US$ in thousands | 1,663,590 | 234,279 | 216,583 | 222,169 | 195,431 | 178,873 | 200,805 | 179,733 | 194,842 | 197,194 | 197,612 | 196,076 | 202,928 | 251,094 | 253,066 | 170,035 | 186,031 | 172,686 | 155,767 | 141,063 |
| ROE | 4.16% | 37.82% | 46.12% | 41.99% | 24.64% | 5.04% | -5.56% | -16.33% | -12.83% | -21.72% | -17.84% | 21.82% | 35.24% | 41.22% | 42.18% | 24.68% | 14.38% | 10.19% | 0.13% | -8.91% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $69,190K ÷ $1,663,590K
= 4.16%
Collegium Pharmaceutical Inc's Return on Equity (ROE) has shown significant fluctuations over the period from March 31, 2020, to December 31, 2024.
The ROE started at -8.91% in March 2020, indicating a negative return relative to shareholders' equity. Over the next few quarters, the ROE gradually improved to reach 14.38% by December 2020 and continued to increase significantly, reaching a peak of 46.12% by June 2024.
However, there were periods of decline in ROE, such as in December 2021, when it dropped to 4.16%, showing a decrease in profitability relative to shareholder equity. Notably, there were also negative ROE values observed in some quarters, such as in June 2022 and September 2022, indicating a loss on equity during those periods.
Overall, the trend in ROE for Collegium Pharmaceutical Inc reflects both periods of strong profitability and challenges in generating returns relative to shareholders' equity. It is essential for stakeholders to closely monitor ROE and understand the factors driving these fluctuations to assess the company's performance effectively.
Peer comparison
Dec 31, 2024